title: Differentiation syndrome with lethal lung injury after arsenic trioxide treatment for myelodysplastic syndrome.
authors.forename: Yishay
authors.initials: Y
authors.lastname: Ofran
authors.forename: Irit
authors.initials: I
authors.lastname: Avivi
authors.forename: Benjamin
authors.initials: B
authors.lastname: Gesundheit
authors.forename: Reuven
authors.initials: R
authors.lastname: Or
authors.forename: Jacob M
authors.initials: JM
authors.lastname: Rowe
authors.forename: Tsila
authors.initials: T
authors.lastname: Zuckerman
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects* / Q000627:therapeutic use; D002454:Cell Differentiation / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D010087:Oxides / Q000009:adverse effects* / Q000627:therapeutic use; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000473:pathology; D012128:Respiratory Distress Syndrome / Q000139:chemically induced*; D013577:Syndrome
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide